Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-26T20:56:04.390Z Has data issue: false hasContentIssue false
  • English
  • Français

N-terminal pro-brain natriuretic peptide in acute Kawasaki disease correlates with coronary artery involvement

Published online by Cambridge University Press:  29 December 2014

Philippe M. Adjagba ,
Laurent Desjardins ,
Anne Fournier ,
Linda Spigelblatt ,
Martine Montigny  and
Nagib Dahdah
Philippe M. Adjagba
Affiliation:
Division of Pediatric Cardiology, Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montréal, Quebec, Canada Department of Cardiology, Hopital de la Mère et de l’Enfant-Lagune, Cotonou, Bénin
Laurent Desjardins
Affiliation:
Division of Pediatric Cardiology, Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montréal, Quebec, Canada School of Medicine, McGill University, Montreal, Quebec, Canada
Anne Fournier
Affiliation:
Division of Pediatric Cardiology, Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montréal, Quebec, Canada
Linda Spigelblatt
Affiliation:
Department of Pediatrics, Maisonneuve Rosemont Hospital, Montréal, Canada
Martine Montigny
Affiliation:
Department of Cardiology, Cité-de-la-Santé Hospital, Laval, Quebec, Canada
Nagib Dahdah*
Affiliation:
Division of Pediatric Cardiology, Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montréal, Quebec, Canada
*
Correspondence to: N. Dahdah, MD, FACC, FASE, FRCPC, Division of Pediatric Cardiology, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, 3175, Côte Sainte-Catherine, Montréal, QC H3T 1C5, Canada. Tel: 514 345 4931, ext 5403; Fax: 514 345 4896; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

We have lately documented the importance of N-terminal pro-brain natriuretic peptide in aiding the diagnosis of Kawasaki disease.

Objectives

We sought to investigate the potential value of N-terminal pro-brain natriuretic peptide pertaining to the prediction of coronary artery dilatation (Z-score>2.5) and/or of resistance to intravenous immunoglobulin therapy. We hypothesised that increased serum N-terminal pro-brain natriuretic peptide level correlates with increased coronary artery dilatation and/or resistance to intravenous immunoglobulin.

Methods

We carried out a prospective study involving newly diagnosed patients treated with 2 g/kg intravenous immunoglobulin within 5–10 days of onset of fever. Echocardiography was performed in all patients at onset, then weekly for 3 weeks, then at month 2, and month 3. Coronary arteries were measured at each visit, and coronary artery Z-score was calculated. All the patients had N-terminal pro-brain natriuretic peptide serum level measured at onset, and the Z-score calculated.

Results

There were 109 patients enrolled at 6.58±2.82 days of fever, age 3.79±2.92 years. High N-terminal pro-brain natriuretic peptide level was associated with coronary artery dilatation at onset in 22.2 versus 5.6% for normal N-terminal pro-brain natriuretic peptide levels (odds ratio 4.8 [95% confidence interval 1.05–22.4]; p=0.031). This was predictive of cumulative coronary artery dilatation for the first 3 months (p=0.04–0.02), but not during convalescence at 2–3 months (odds ratio 1.28 [95% confidence interval 0.23–7.3]; p=non-significant). Elevated N-terminal pro-brain natriuretic peptide levels did not predict intravenous immunoglobulin resistance, 15.3 versus 13.5% (p=1).

Conclusion

Elevated N-terminal pro-brain natriuretic peptide level correlates with acute coronary artery dilatation in treated Kawasaki disease, but not with intravenous immunoglobulin resistance.

Keywords

Kawasaki diseasepredictioncoronary artery involvementN-terminal pro-brain natriuretic peptidepredictive value
Type
Original Articles
Information
Cardiology in the Young , Volume 25 , Issue 7 , October 2015 , pp. 1311 - 1318
Check for updates
Copyright
© Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Kavey, RE, Allada, V, Daniels, SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on population and prevention science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006; 114: 2710–2738; [Epub ahead of print].Google Scholar
2. Manlhiot, C, Yeung, RS, Clarizia, NA, Chahal, N, McCrindle, BW. Kawasaki disease at the extremes of the age spectrum. Pediatrics 2009; 124: e410–e415; [Epub ahead of print].Google Scholar
3. Burns, JC, Newburger, JW. Genetics insights into the pathogenesis of Kawasaki disease. Circ Cardiovasc Genet 2012; 5: 277–278.Google Scholar
4. Onouchi, Y. Genetics of Kawasaki disease: what we know and don't know. Circ J 2012; 76: 1581–1586; [Epub ahead of print].CrossRefGoogle ScholarPubMed
5. Tsuda, E, Kamiya, T, Ono, Y, Kimura, K, Kurosaki, K, Echigo, S. Incidence of stenotic lesions predicted by acute phase changes in coronary arterial diameter during Kawasaki disease. Pediatr Cardiol 2005; 26: 73–79.Google Scholar
6. Newburger, JW, Takahashi, M, Beiser, AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633–1639.Google Scholar
7. Durongpisitkul, K, Soongswang, J, Laohaprasitiporn, D, Nana, A, Prachuabmoh, C, Kangkagate, C. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003; 24: 145–148; [Epub ahead of print].CrossRefGoogle ScholarPubMed
8. Fukunishi, M, Kikkawa, M, Hamana, K, et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000; 137: 172–176.Google Scholar
9. Newburger, JW, Takahashi, M, Gerber, MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004; 114: 1708–1733.Google Scholar
10. de Lemos, JA, McGuire, DK, Drazner, MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316–322.Google Scholar
11. Nakao, K, Ogawa, Y, Suga, S, Imura, H. Molecular biology and biochemistry of the natriuretic peptide system. II: natriuretic peptide receptors. J Hypertens 1992; 10: 1111–1114.Google Scholar
12. Vanderheyden, M, Bartunek, J, Goethals, M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 2004; 6: 261–268.CrossRefGoogle ScholarPubMed
13. Tang, WH. B-type natriuretic peptide: a critical review. Congest Heart Fail 2007; 13: 48–52.Google Scholar
14. Dahdah, N, Siles, A, Fournier, A, et al. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol 2009; 30: 810–817; [Epub ahead of print].Google Scholar
15. McNeal-Davidson, A, Fournier, A, Spigelblatt, L, et al. Value of amino-terminal pro B-natriuretic peptide in diagnosing Kawasaki disease. Pediatr Int 2012; 54: 627–633; [Epub ahead of print].CrossRefGoogle ScholarPubMed
16. Lee, DW, Kim, YH, Hyun, MC, Kwon, TC, Lee, SB. NT-proBNP as a useful tool in diagnosing incomplete Kawasaki disease. Korean Pediatr 2010; 53: 519–524.Google Scholar
17. Dahdah, N, Fournier, A. Natriuretic peptides in Kawasaki disease: the myocardial perspective. Diagnostics 2013; 3: 1–12.Google Scholar
18. Kawamura, T, Wago, M. Brain natriuretic peptide can be a useful biochemical marker for myocarditis in patients with Kawasaki disease. Cardiol Young 2002; 12: 153–158.CrossRefGoogle ScholarPubMed
19. Kawamura, T, Wago, M, Kawaguchi, H, Tahara, M, Yuge, M. Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int 2000; 42: 241–248.Google Scholar
20. Bang, S, Yu, JJ, Han, MK, et al. Log-transformed plasma level of brain natriuretic peptide during the acute phase of Kawasaki disease is quantitatively associated with myocardial dysfunction. Korean J Pediatr 2011; 54: 340–344; [Epub ahead of print].Google Scholar
21. Kim, HK, Oh, J, Hong, YM, Sohn, S. Parameters to guide retreatment after initial intravenous immunoglobulin therapy in Kawasaki disease. Korean Circ J 2011; 41: 379–384; [Epub ahead of print].CrossRefGoogle ScholarPubMed
22. Kim, SY, Han, MY, Cha, SH, Jeon, YB. N-terminal pro-brain natriuretic peptide (NT proBNP) as a predictive indicator of initial intravenous immunoglobulin treatment failure in children with Kawasaki disease: a retrospective study. Pediatr Cardiol 2013; 34: 1837–1843; [Epub ahead of print].Google Scholar
23. Ogata, S, Ogihara, Y, Honda, T, Kon, S, Akiyama, K, Ishii, M. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics 2012; 129: e17–e23; [Epub ahead of print].CrossRefGoogle ScholarPubMed
24. Sleeper, LA, Minich, LL, McCrindle, BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 2011; 158: 831.e3–835.e3; [Epub ahead of print].Google Scholar
25. Nir, A, Lindinger, A, Rauh, M, et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009; 30: 3–8; [Epub ahead of print].Google Scholar
26. Dallaire, F, Dahdah, N. New equations and a critical appraisal of coronary artery Z scores in healthy children. J Am Soc Echocardiogr 2011; 24: 60–74; [Epub ahead of print].CrossRefGoogle Scholar
27. Newburger, JW, Takahashi, M, Gerber, MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004; 114: 1708–1733.CrossRefGoogle Scholar
28. Kampmann, C, Wiethoff, C, Wenzel, A, et al. Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe. Heart 2000; 83: 667–672.CrossRefGoogle ScholarPubMed
29. Falcini, F. Kawasaki disease. Curr Opin Rheumatol 2006; 18: 33–38.Google Scholar
30. Kaneko, K, Yoshimura, K, Ohashi, A, Kimata, T, Shimo, T, Tsuji, S. Prediction of the risk of coronary arterial lesions in Kawasaki disease by brain natriuretic peptide. Pediatr Cardiol 2011; 32: 1106–1109; [Epub ahead of print].Google Scholar
31. Yoshimura, K, Kimata, T, Mine, K, Uchiyama, T, Tsuji, S, Kaneko, K. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease. J Pediatr 2013; 162: 1205–1209; [Epub ahead of print].CrossRefGoogle ScholarPubMed
32. Shiraishi, M, Fuse, S, Mori, T, et al. N-terminal pro-brain natriuretic peptide as a useful diagnostic marker of acute Kawasaki disease in children. Circ J 2013; 77: 2097–2101; [Epub ahead of print].CrossRefGoogle ScholarPubMed
33. Kurotobi, S, Kawakami, N, Shimizu, K, et al. Brain natriuretic peptide as a hormonal marker of ventricular diastolic dysfunction in children with Kawasaki disease. Pediatr Cardiol 2005; 26: 425–430.Google Scholar
34. Printz, BF, Sleeper, LA, Newburger, JW, et al. Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. J Am Coll Cardiol 2011; 57: 86–92.CrossRefGoogle ScholarPubMed
35. Sato, YZ, Molkara, DP, Daniels, LB, et al. Cardiovascular biomarkers in acute Kawasaki disease. Int J Cardiol 2013; 164: 58–63; [Epub ahead of print].Google Scholar